Eupraxia Pharmaceuticals Files 6-K with Financials
Ticker: EPRX · Form: 6-K · Filed: Aug 13, 2025 · CIK: 1581178
Sentiment: neutral
Topics: financial-reporting, sec-filing, pharmaceuticals
TL;DR
Eupraxia Pharmaceuticals dropped its latest financials (June 30, 2025) in a 6-K filing, check it out.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on August 13, 2025, reporting for the month of August 2025. The filing includes consolidated financial statements for the three and six months ended June 30, 2025, and Management's Discussion and Analysis. These documents are incorporated by reference into Eupraxia's Registration Statements on Form F-10 (File No. 333-276586) and Form S-8 (File No. 333-278534).
Why It Matters
This filing provides investors with updated financial statements and management's analysis, offering insights into the company's performance and financial health for the period ending June 30, 2025.
Risk Assessment
Risk Level: low — This filing is a routine financial disclosure and does not contain new material events or significant changes.
Key Players & Entities
- EUPRAXIA PHARMACEUTICALS INC. (company) — Filer
- 333-276586 (registration_statement_file_number) — Incorporated by reference into Form F-10
- 333-278534 (registration_statement_file_number) — Incorporated by reference into Form S-8
- June 30, 2025 (date) — Financial reporting period end
FAQ
What period do the included financial statements cover?
The included financial statements cover the three and six months ended June 30, 2025.
Which registration statements incorporate this Form 6-K by reference?
Exhibits 99.1 and 99.2 of this Form 6-K are incorporated by reference into Eupraxia's Registration Statement on Form F-10 (File No. 333-276586) and its Registration Statement on Form S-8 (File No. 333-278534).
What is the filing date of this Form 6-K?
This Form 6-K was filed as of August 13, 2025.
What is Eupraxia Pharmaceuticals Inc.'s principal executive office address?
The principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada V8R 5G4.
Does Eupraxia Pharmaceuticals Inc. file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Stats: 246 words · 1 min read · ~1 pages · Grade level 9.4 · Accepted 2025-08-12 18:03:26
Filing Documents
- d54647d6k.htm (6-K) — 11KB
- d54647dex991.htm (EX-99.1) — 457KB
- d54647dex992.htm (EX-99.2) — 288KB
- d54647dex993.htm (EX-99.3) — 26KB
- d54647dex994.htm (EX-99.4) — 12KB
- d54647dex995.htm (EX-99.5) — 12KB
- g54647g24q18.jpg (GRAPHIC) — 19KB
- g54647g37u32.jpg (GRAPHIC) — 10KB
- 0001193125-25-179135.txt ( ) — 847KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: August 12, 2025 By: /s/ Alex Rothwell Name: Alex Rothwell Title: Chief Financial Officer